Buy or sell CRISPR Therapeutics stock pre IPO via an EquityZen fund
EquityZen is a marketplace for shares of proven pre IPO tech companies
CRISPR Therapeutics Stock
CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform.
About CRISPR Therapeutics Stock
CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. They have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from their scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing. CRISPR Therapeutics’ vision is to cure serious human diseases at the molecular level using CRISPR-Cas9. The company is headquartered in Basel, Switzerland and has operations in London, UK.
Founder & CFO
Founder & Chief Executive Officer
Chief Scientific Officer
Forbes - Nov, 19 2019
TechCrunch - Nov, 26 2018
TechCrunch - Nov, 25 2018
Nasdaq Place (press release) - Jun, 26 2018
StreetInsider.com - Jun, 16 2018
Seeking Alpha - Jun, 11 2018
Xconomy - May, 30 2018
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase